- Therapeutic Areas of Interest
- Research Pipeline
- Development Process
- Clinical Trials
- Research Organization Profiles
- Research and Development Disclaimer
Compound Profiles
QR-333 |
Diabetic Peripheral Neuropathy |
| Concentrated and standardized nutrient based active compound dozed in a topical cream designed to reduce oxidative stress and treat symptom of Diabetic peripheral neuropathy, a nerve disorder that can lead to numbness, constant pain or extreme sensitivity to a stimulus. + More |
QR-440, QR-440(c)
|
Arthritis |
| A botanical compound of concentrated spice type plant Derivatives, QR-440 has been shown in pre-clinical studies to have a significant anti-inflamatory effect. + More |
Safe Harbor Statement for Research and Development
The Quigley Corporation makes no representation that the US Food and Drug Administration or any other regulatory agency will grant an Investigational New Drug ("IND") or take any other action to allow its formulations to be studied or/and for any Investigational New Drug to be marketed. Furthermore, no claim is made that potential medicine discussed herein is safe, effective, or approved by the Food and Drug Administration. Additionally, data that demonstrates activity or effectiveness in animals or in vitro tests do not necessarily mean the formula test compound, referenced herein will be effective in humans. Safety and effectiveness in humans will have to be demonstrated by means of adequate and well controlled clinical studies before the clinical significance of the formula test compound is known. Readers should carefully review the risk factors described in filings the Company files from time to time with the Securities and Exchange Commission.
![[Qlogo.gif] [Qlogo.gif]](http://www.quigleypharma.com/uploads/images/Qlogo.gif)